Interests of the 'artifical stomach' techniques to study antacid formulations: Comparison with in vivo evaluation

Fundamental and Clinical Pharmacology

Volumn 12, Issue 6, 1998, Pages 573-583

  Vatier, J ^a,b,c   Celice Pingaud C ^a,c   Farinotti, R ^b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Antacids; Artificial stomach model; Gastric pH metry; Intragastric titration

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM SALT; ANTACID AGENT; GUAR GUM; ISUDRINE; MAGALDRATE; MAGNESIUM OXIDE; MAGNESIUM SALT; RENNIE; SIMALUMAG; SUCRALFATE; ULCAL; UNCLASSIFIED DRUG; PENTAGASTRIN;

DRUG BINDING; DRUG DETERMINATION; DRUG FORMULATION; DUODENOGASTRIC REFLUX; DUODENUM ULCER; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; STOMACH MUCOSA; STOMACH PH; ARTIFICIAL ORGAN; BIOLOGICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; PH; SECRETION; STOMACH ACID; STOMACH EMPTYING;

ANTACIDS; ARTIFICIAL ORGANS; CHEMISTRY, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; GASTRIC ACID; GASTRIC EMPTYING; GASTRIC MUCOSA; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, BIOLOGICAL; PENTAGASTRIN;

EID: 0032217316     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00989.x     Document Type: Review

References (60)

1. Berchtold P, Reinhart WH, Niederhauser V et al. In vitro tests overestimate in vivo neutralizing capacity of antacids in presence of food. Dig Dis Sci 1985 ; 30 : 522-8
2. Berstad A, Weherg R. Antacids for peptic ulcer: do we have anything better? Scand J Gastroenterol 1986 ; suppl 125 : 32-9
3. Carlson GL, Malagelada JR. Chemistry of the antacids: its relevance to antacid therapy. In: Halter F, ed. Antacids in the Eighties. Urban and Schwarzenberg, Munich, 1982
4. Caugan T, Yvon M, Thirovin S et al. Characterization of products from in vivo and in vitro gastric digestion of milk remplaces whey proteins? J Agric Food Chem 1992 ; 40 : 1340-67
5. 2 receptor-antagonists he taken in an effervescent formulation? Eur J Gastroenterol Hepatol 1991 ; 3 : 38 (abstr)
6. Dollinger HC, Holzberg E. Beeinflüssen Antacida mit hohem Saürebindungsvermögen den Mineralaushalt? Med Klin 1986 ; 81 : 15-9
7. Drake D, Hollander D. Neutralising capacity and cost effectiveness of antacids. Ann Intern Med 1981 ; 94 : 215-7
8. Dubicourt JC, Hemery P, Gignoux C et al. Réduction du reflux gastro-œsophagien postprandial par l'alginate de sodium suspension. Etude pH-métrique multicentrique chez 21 malades. Presse Med 1988 ; 17 : 683-5
9. Duval de Laguierce T, Corrizi F, Vallot T et al. Importance du choix du pH de titration lors de la mesure in vivo par titration intragastrique (Fordtran et Walsh) d'un antiacide chez le sujet sain. Gastroentérol Clin Biol 1986 ; 10 (2 bis) : 159 (abstr)
10. Over the counter drugs: proposal for eslablishement a monograph for OTC antacid products. Federal Register Test 1973 ; 38 : 8714-24
11. 2 antgonists. Gastroenterology 1985 ; 88 : 1842-57
12. Fordtran JS, Morawski SG, Richardson CT. In vivo and in vitro evaluation of liquid antacids. N Eng J Med 1973 ; 288 : 923-8
13. Fordtran JS, Walsh JH. Gastric acid secretion rate and buffer content of the stomach after eating. J. Clin Invest 1973 ; 52 : 645-52
14. Fuchs C. Antacids. Their function, formulation and evaluation. Drug Cosm Ind 1949 ; 64 : 692-773
15. Galmiche JP, Bruley des Varannes S. Gastric pH-metry: clinical relevance in investigation of gastric fonction. In: Scarpignato D, Bianchi Porro G, eds. Frontiers of Gastrointestinal Research, Vol 17, Basel: Karger; 1990. p 32-54
16. George JD. New clinical method for measuring the rate of gastric emptying: the double sampling test meal. Gut 1968 ; 9 : 237-42
17. Gitzinger C, Schwan TV. Discrepancy between in vivo and in vitro neutralisation capacity. Der Deutsche Apotheker 1984 ; 36 : 158-67
18. Grossman MI. Duration of action of antacids. Am J Dis Dis 1956 ; 1 : 453-4
19. Guillet J, Role C, Imbert Y et al. 99 m TC labelled colloïdal aluminium phosphate (CAP) and sucralfate (S). Are they suitable to diagnose and follow up œsogastroduodenal ulcerations? Eur J Nucl Med 1988 ; 14 : 214 (abstr)
20. Hardy JG, Hooper G, Ravelli GP et al. A comparison of the gastric retention of a sucralfate gel and a sucralfate suspension. Eur J Pharm Biopharm 1993 ; 39 : 70-4
21. Ingelfinger FG. Gastric analysis: Ancient but going strong. N Engl Med 1973 ; 288 : 964-5
22. Isal JP, Vatier J, Vitré MT et al. Etude pharmacologique des médicaments antiacides: relation entre activité in vitro et in vivo. J Pharm Clin 1986 ; 4 : 385-97
23. Isenberg JL, Hogan DL, Koss MA et al. Human duodenal mucosal bicarbonate secretion. Evidence for basal secretion and stimulation by hydrochloric acid and a synthetic prostaglandin E1. Gastroenterology 1986 ; 91 : 370-8
24. Isenberg JL, Hogan DL, Koss MA et al. Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer. N Engl J Med 1987 ; 316 : 374-9
25. Johnson EH, Duncan J. The chemical testing of antacids. Quart J Pharm Pharmacol 1945 ; 18 : 251-6
26. Lambert M, Minaire Y. Le traitement antiacide de l'ulcère gastroduodénal. Gastroenterol Clin Biol 1977 ; 1 : 3-7
27. Marteau P, Minekus M, Havenaar R, Huis in 't Veld JHJ. Survival of lactic acid bacteria in a dynamic model of the stomach and small intestine: validation and the effect of bile. J Dairy Sci 1997 ; 80 : 1031-7
28. May HA, Hardy JG, Wilson CG. Monitoring radiolabelled antacid preparations in the stomach. Int J Pharm 1989 ; 19 : 169-76
29. Mela GS, Savarino V, Moretti M et al. Antimony and glass electrode can be used interchangeably in 24 h study of gastric activity. Dig Dis Sci 1990 ; 35 : 1473-81
30. Merrouche M, Mignon M, Rigaud D et al. Conséquences de l'acidification antrale et duodénale sur le débit acide, la réponse gastrinique et la vidange gastrique chez l'ulcéreux duodénal et le sujet normal. Gastroentérol Clin Biol 1985 ; 9 : 902-10
31. Minekus M, Marteau P, Havenaar R, Huis in 't Veld JHJ. A multi-compartimental dynamic computer-controlled model simulating the stomach and small intestine. ATLA 1995 ; 23 : 197-209
32. Moss HA, Washington N, Greaves JL et al. Antireflux agents: stratification or floatation. Eur J Gastroentérol Hepatol 1990 ; 2 : 45-51
33. Nail SL, White JL, Hem SL. Structure of aluminium hydroxide gel. I: initial precipitate. J Pharm Sci 1976 ; 65 : 1188-91
34. Papazian A, Vatier J, Bosser J et al. Comment choisir un bon topique digestif? Nouvelles bases rationnelles du choix thérapeutique. Entretiens de Bichat Thérapeut 1985 ; 88-92
35. Rossett NE, Rice ML. An in vitro evuluation of the efficacy of more frequently used antacids with particular attention to tablets. Gastroentérology 1954 ; 26 : 490-5
36. Rougier P, Mignon M. Intérêt de la titration intragastrique (méthodcede de Fordtran et Walsh) dans l'exploration fonctionnelle de l'estomac. Gastroentérol Clin Biol 1978 ; 2 : 765-9
37. Smyth RD, Herezeg T, Wheatley TA, Hause W, Reavey-cantwell NH. Correlation of in vitro and in vivo methodology for evaluation of antacids. J Pharm Sci 1976 ; 65 : 1045-7
38. Steinberg WH, Hutchins HN, Pick P et al. Automated technique for determining dissolution and reaction rate of antacids. J Pharm Sci 1965 ; 54 : 625-33
39. Stoddard CJ, Morgan GE. Comparative intragastric pH profile of Algicon versus Gaviscon. Br J Clin Pract 1989 ; 43 (supp 66) : 29-34
40. Uusitalo A, Keyriläinen O. Effects of antacids on intragastric pH in healthy subjects and duodenal ulcer patients. Influence of the size of the antacid dose and of anticholinergics. Clin Physiol 1983 ; 3 : 503-11
41. + et de leur classification. Gastroentérol Clin Biol 1983 ; 7 : 573-9
42. Vatier J, Forichon J, Vitré MT et al. Predictive value of the in vitro antacid determination on pharmacological assay in man. J Pharm Chir 1986 ; 5 : 399-411
43. Vatier J, Lionnet F, Vitré MT. Activité antiacide du cation aluminium: comparaison de l'effet de l'hydroxyde et du phosphate in vitro en systèmes fermés et ouverts. Gastroentérol Clin Biol 1987 ; 11 : 758-63
44. Vatier J, Lionnet, Vitré MT, Mignon M. A model of an 'artificial stomach' for assessing the characteristics of an antacid. Aliment Pharmacol Ther 1988 ; 2 : 461-70
45. Vatier J, Vitré MT, Vallot T et al. Assessment of antacid characteristics of drugs containing a combination of aluminium and magnesium salts using the 'artificial stomach' model. Arzneim Forsch 1990 ; 40 : 42-8
46. Vatier J, Vitré MT, Vallot T et al. Capacité d'induction d'un gradient de pH et activité antiacide des pansements gastro-œsophagiens. Etude pharmacologique in vitro en utilisant le modèle de «l'estomac artificiel». Gastroentérol Clin Biol 1990 ; 14 : 414-22
47. Vatier J, Gao Z, Fu-Cheng XM et al. Evidence for the interaction between antacid and gastric mucosa using an 'artificial stomach' model including gastric mucosa. J Pharmacol Exp Therap 1992 ; 263 : 1206-11
48. Vatier J, Malikova-Sekera E, Vitré MT et al. 'An artificial stomach-duodenum' model for the in vitro evaluation of an antacid. Aliment Pharmacol Ther 1992 ; 6 : 447-58
49. Vatier J, Vitré MT, Mignon M. Activité antiacide d'un mélange d'hydroxyde d'aluminium, de trisilicate de magnésium et de diméticone in vitro dans le modele de «l'estomac duodénum artificiels» incluant ou non un fragment de muqueuse antrale de pore. Med Chir Dig 1992 ; 21 : 471-4
50. Vatier J, Harman A, Castela N et al. Interaction of cimetidine and ranitidine with aluminium containing antacids and a clay-containing gastric protective drug in an 'artificial stomach-duodenum' model. J Pharm Sci 1994 ; 83 : 962-6
51. Vatier J, Ramdani A, Vitré MT et al. Antacid activity of calcium carbonate and hydrotalcit tablets. Comparison between in vitro evaluation using the 'artificial stomach-duodenum' model and in vivo pH-metry in healthy volunteers. Arzneim Forsch Drug Res 1994 ; 14 : 815-9
52. Vatier J, Cai S, Célice-Pingaud C et al. In vitro assessment of antacid efficacy using a computer-controlled 'artificial stomach-duodenum' model reproducing gastroduodenal flux regulation. Therapie 1996 ; 5 : 147-54
53. Vatier J, Cai S. Slama A et al. Activité antiacide du couple citrate-bicarbonate des formes effervescentes de Ranitidine. Analyse in vitro à l'aide du modèle de «l'estomac-duodénum artificials». Therapie 1996 ; 51 : 139-46
54. Vatier J, Vallot T, Farinotti R. Les antiacides : des propriétés pharmacologiques multiples et trop souvent méconnues. J Pharm Clin 1996 ; 15 : 41-51
55. Vatier J, Vallot T, In: Vatier J, ed. Étude Pharmacologique des Antiacides. Exploration de la Sécrétion Gastrique. Paris: Éditions Médicales Internationales: 1997. p 171-85
56. Vatier J, Célice-Pingaud C, Farinotti R. A computerized 'artificial stomach' model to assess sodium alginate-induced pH gradient. Inter J Pharm 1998 ; 163 : 225-9
57. Washington N, Wilson CG, Davis SS. Evaluation of 'raft-forming' antacid neutralising capacity: in vitro and in vivo correlations. Int J Pharm Sci 1985 ; 27 : 279-86
58. Washington N, Washington C, Wilson CG, Davis SS. The effect of inclusion of aluminium hydroxide in alginate-contining raft-forming antacids. Int J Pharm Sci 1986 ; 28 : 139-43
59. Washington N, Washington C, Wilson CG. Gastric distribution and residence time of two anti-reflux formulations. Int J Pharm Sci 1987 ; 39 : 163-71
60. Yvon M, Beucher S. Scanf FP et al. In vitro simulation of gastric digestion of milk proteins: comparison between in vitro and in vivo data. J Agric Food Chem 1992 ; 40 : 239-44